InvestorsHub Logo

TOB

Followers 162
Posts 5764
Boards Moderated 1
Alias Born 09/15/2010

TOB

Re: eddiebali post# 22213

Friday, 01/25/2013 8:49:07 PM

Friday, January 25, 2013 8:49:07 PM

Post# of 402966

I wasnt aware that Kevetrin was being tested in combination with Sunitib.

Can anyone direct me towards any other possible combinations that Kevetrin is being used with. -eddiebali



The other combination study with CTIX Kevetrin that we know of is the combination with Cytarabine.


The clinical phase 1b trial is titled “A Multi-Center, Open-Label, Phase 1B Study of Kevetrin with Cytarabine in patients with Acute Myelogenous Leukemia (AML)”

The University of Bologna in Italy (the “University”) and The Italian Cooperative Study Group on Chronic Myeloid Leukemia (ICSG on CML) and Acute Leukemia (GIMEMA Group) are sponsoring the clinical trials. Cellceutix has been advised that the submission for approval for the clinical trials are on schedule and the trials are expected to begin during the first half of 2013.

“Kevetrin has garnered the attention of some of the world’s foremost authorities in oncology,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The University of Bologna has a distinguished history as a European leader in cancer research with a particular expertise in the field of hematological cancers. We could not be more pleased that this institution sees the potential for Kevetrin as a new drug candidate for AML and look we forward to building upon this special relationship with this esteemed institution.”



We already know this about the completed pre-clincal research that is leading to the trial.

The University has conducted pre-clinical research that they shared with us but asked that we not disclose the data as they “plan to publish it at a later day.” A very brief summary of the data showed Kevetrin causing apoptosis (programmed cell death) in cancerous cells in addition to sensitizing and optimizing the cells to maximize the effectiveness of drugs used in combination with Kevetrin.



It is standard procedure for the full data to be withheld when publication in peer reviewed journals is anticipated.

Cell death of cancer cells is the money quote.

And we see again it is the mechanism of Kevetrin in increasing the effectiveness of drugs in combination that is being studied.

.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News